Visionary’s portfolio company Tear Film Innovations’ iLux spotlighted in an Ophthalmology Management Article about Treatment of Meibomian gland disfunction (MGD).
DetailsOrasis Pharmaceuticals completes $13MM Series B financing led by Visionary Ventures, with participation from Sequoia Capital, SBI (Japan) Innovation Ventures, LifeSci Venture Partners, and other private investors
DetailsTear Film Innovations completes $8.5MM Series B financing co-led by Visionary Ventures and Bluestem Capital
DetailsTear Film Innovations completes $9MM Series A financing co-led by Visionary Ventures and Tigris Ventures
DetailsPWC Healthcare MoneyTree Report Q2 2017 Names Visionary Ventures the Number 3 Most Active Venture Fund in Healthcare.
DetailsFunding for IanTECH’s Next Generation Ophthalmic Device Supports Goal to Alleviate Cataract-induced Blindness in 25 Million.
DetailsTearClear closes series A financing and introduces leadership team of accomplished ophthalmology veterans with the proceeds going to advance the development of the Company’s delivery system for preservative-free ophthalmic drugs.
DetailsThe Economic Impact of the Ophthalmic Goods Manufacturing Industry on the Southern California Economy.
Details
